60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.14), FiscalAI reports. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.27 million.
60 Degrees Pharmaceuticals Price Performance
SXTP traded down $0.01 during midday trading on Monday, reaching $0.51. 51,938 shares of the company’s stock were exchanged, compared to its average volume of 1,436,917. 60 Degrees Pharmaceuticals has a 1-year low of $0.46 and a 1-year high of $8.62. The business’s 50-day moving average price is $0.94 and its 200 day moving average price is $1.65. The stock has a market capitalization of $1.79 million, a PE ratio of -0.11 and a beta of 2.47.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, September 21st. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, 60 Degrees Pharmaceuticals has an average rating of “Hold” and an average price target of $13.85.
View Our Latest Stock Analysis on 60 Degrees Pharmaceuticals
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for infectious diseases, particularly malaria and other parasitic infections. Its portfolio includes tafenoquine, an antimalarial medicine marketed in the United States as ARAKODA for the prevention of malaria in adults. The company is also studying tafenoquine for potential use against babesiosis, a tick-borne parasitic disease. These development programs are investigational; tafenoquine’s approval for malaria prevention does not extend to babesiosis.
See Also
- Five stocks we like better than 60 Degrees Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
